Roche’s PD-L1 inhibitor demonstrates durable response in RET-mutant thyroid cancer, offering a new option for patients with limited …
Roche’s PD-L1 inhibitor demonstrates durable response in RET-mutant thyroid cancer, offering a new option for patients with limited …
Pfizer’s ambitious gene therapy for Duchenne muscular dystrophy fails to meet efficacy targets, prompting strategic retreat and industry-wide …
Semaglutide’s latest trial reveals significant reduction in heart failure hospitalizations, expanding its role in cardiometabolic care.
Regulatory approval marks a pivotal moment for psychedelic medicine, as COMPASS Pathways prepares to test psilocybin in treatment-resistant …
GSK’s long-acting biologic reduces exacerbations and improves lung function in eosinophilic asthma, offering a potential once-yearly treatment option.
NIH-supported study demonstrates that turning off the prion protein gene can dramatically reduce toxic build-up, offering hope for …
NIH-backed research reveals that a simple skin test may revolutionize early diagnosis of Parkinson’s and related neurodegenerative disorders.
Despite high hopes, Roche’s anti-amyloid antibody shows no significant benefit in slowing cognitive decline, prompting reevaluation of Alzheimer’s …
The bispecific antibody earns full approval after demonstrating durable responses in heavily pre-treated patients.
The biotech firm discontinues its ReFocus-ALZ and ReThink-ALZ trials, marking a major shift in its neurodegenerative disease strategy.
